Pharmacovigilance doesn't wait.
We respond in 2 seconds. GxP-compliant.

Pharmacovigilance refers to the monitoring of drug safety after market authorisation, in order to systematically record and evaluate side effects and risks. Contact centres play a central role in this process, as they are often the first point of contact for reports from patients, doctors and pharmacists. A professional service provider should implement structured processes for receiving adverse drug reaction reports (ADRs) that comply with regulatory requirements (EU Regulation 1235/2010). Documentation must be complete and precise. Critical reports should be forwarded within statutory deadlines (15 days for serious, 90 days for non-serious ADRs). Staff should be GCP-trained and familiar with pharmacovigilance processes. Follow-up processes should be established for incomplete reports. Comprehensive documentation is also required by authorities such as BfArM and EMA.

Contact centres in the pharmaceutical industry are subject to strict regulatory requirements to ensure quality, safety and compliance. GMP qualification (Good Manufacturing Practice) should be in place for pharmaceutical processes, particularly where product information or batch traceability is involved. GDP compliance (Good Distribution Practice) is required when passing on product information. Pharmacovigilance compliance in accordance with EU Regulation 1235/2010 must be ensured. GDPR-compliant processing of sensitive health data (Art. 9 GDPR) is mandatory. Documentation obligations for all customer interactions must be met to ensure audit trails. Regular audits by QA and authorities should be conducted. SOPs and training materials should be available and up to date at all times.

Patient Support Programmes (PSPs) are particularly important for complex therapies and chronic conditions to improve therapy adherence and provide comprehensive patient support. A specialised contact centre should offer therapy support and adherence assistance. Medication counselling and reminder services should be implemented to prevent therapy discontinuation. Adverse event management and pharmacovigilance should be integrated. Cost reimbursement support should help patients with prescriptions and health insurance communication. Psychosocial support should be offered for chronic conditions. PSPs are especially essential for biologics, oncology and rare diseases. Staff should be medically trained (pharmaceutical technicians, medical assistants, nurses).

Medical expertise is essential in a pharmaceutical contact centre to provide qualified and regulatory-compliant advice. Staff should ideally be medically qualified (pharmaceutical technicians, pharmacists, medical assistants, nurses). All agents should complete product-specific training covering indication, mechanism of action and side effects. Regular updates should be provided when new study data or approval changes occur. Access to specialist information and internal knowledge databases should be ensured. Close collaboration with Medical Affairs should be established for escalating complex questions. GCP training (Good Clinical Practice) should be mandatory for all staff.

Health data is among the most sensitive data under Art. 9 GDPR and requires the highest security measures. Encrypted data transmission and storage on EU servers should be ensured. Role-based access controls should ensure that only authorised staff have access. Pseudonymisation of patient data should be applied wherever possible. Automatic deletion periods in accordance with retention obligations should be implemented. Regular data protection audits by external auditors should be conducted. Training on data protection and confidentiality should be mandatory. ISO 27001 certification for information security should be in place.

Medical Information Services (MIS) are specialised services that answer medical and scientific enquiries about medicinal products. A professional service provider should ensure qualified responses to medical enquiries from doctors, pharmacists and patients. Provision of specialist information and study data should be possible. Off-label use enquiries should be answered in a legally compliant manner. Interaction checks and contraindications should be assessable. All responses should be approved by pharmacists or physicians. An average response time of less than 24 hours should be targeted.

Quality assurance is of the utmost importance in the pharmaceutical sector due to regulatory requirements and patient safety. GMP-compliant SOPs should exist for all processes and be regularly updated. 100% call monitoring should be carried out for pharmacovigilance reports. Regular quality audits should be conducted by internal and external auditors. Deviation management should be implemented for deviations from SOPs. CAPA processes (Corrective and Preventive Actions) should be established for continuous improvement. KPI tracking should measure response times, completeness and compliance. A low error rate (< 0.1%) should be targeted.

Pharmaceutical contact centre services are more cost-intensive than standard contact centres due to high compliance requirements and the need for medically qualified staff. Typical pricing models include: €2.00–3.50 per telephone minute (higher than standard call centres due to medical staff and regulations), €5.00–10.00 per pharmacovigilance report (including full documentation and follow-up), €3,000–5,000 per agent/month for seat-based models, or flat rates for patient support programmes (€10,000–30,000/month depending on patient numbers and complexity). Exact costs depend on factors such as therapy complexity, required qualifications, languages and SLA requirements.